The mission of the Mayo Clinic Cancer Center is to promote and facilitate basic and clinical research on the incidence, etiology, and progression of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis and therapy. The ultimate goal is to relieve the burdens of illness in patients with cancer. Accordingly, Mayo Clinic Cancer Center research is broad and interdisciplinary, but highly cancer focused. Professional and lay education activities are excellent and expansive, and clinical and psychosocial care of patients are of the highest quality and humanistic. These aggregate characteristics form the basis for our request for CCSG support and to be designated by the National Cancer Institute as a Comprehensive Cancer Center. The scientific objectives will be achieved by seven established programs of the MCCC. These programs are assigned to three portfolios each managed by an Associate Director, namely: Basic Science (Immunology, Developmental Therapeutics and Cancer Genetics Program); Clinical and Translational Research Portfolio (Clinical and Translational Research, Prostate Cancer, and Imaging Programs); and a Population Sciences Portfolio with a single Program in Genetic Epidemiology, Prevention and Control. There is a single Developing Program for Breast Cancer Cell Biology. Research in these programs will be facilitated by nine shared resources for Statistics and Support Services, Pharmacy, Tissue Acquisition, Pharmacology, Gene Discovery, Cytogenetics, Molecular Biology, Protein Chemistry, and Flow Cytometry and Optical Morphology). An extensive non-CCSG funded Education Program rounds out the CCSG request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-25S1
Application #
2849481
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Shafik, Hasnaa
Project Start
1988-03-01
Project End
2002-02-28
Budget Start
1999-05-27
Budget End
2000-02-29
Support Year
25
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications